Form 10-Q China Foods Holdings For: Jun 30

August 14, 2026 11:02 AM EDT
false --12-31 Q2 0001310630 0001310630 2026-01-01 2026-06-30 0001310630 2026-08-14 0001310630 2026-06-30 0001310630 2025-12-31 0001310630 us-gaap:RelatedPartyMember 2026-06-30 0001310630 us-gaap:RelatedPartyMember 2025-12-31 0001310630 srt:DirectorMember 2026-06-30 0001310630 srt:DirectorMember 2025-12-31 0001310630 CFOO:RelatedCompanyMember 2026-06-30 0001310630 CFOO:RelatedCompanyMember 2025-12-31 0001310630 2026-04-01 2026-06-30 0001310630 2025-04-01 2025-06-30 0001310630 2025-01-01 2025-06-30 0001310630 us-gaap:CommonStockMember 2025-12-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001310630 us-gaap:RetainedEarningsMember 2025-12-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001310630 us-gaap:CommonStockMember 2026-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001310630 us-gaap:RetainedEarningsMember 2026-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001310630 2026-03-31 0001310630 us-gaap:CommonStockMember 2024-12-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001310630 us-gaap:RetainedEarningsMember 2024-12-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001310630 2024-12-31 0001310630 us-gaap:CommonStockMember 2025-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001310630 us-gaap:RetainedEarningsMember 2025-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001310630 2025-03-31 0001310630 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001310630 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001310630 2026-01-01 2026-03-31 0001310630 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001310630 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001310630 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001310630 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001310630 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001310630 2025-01-01 2025-03-31 0001310630 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001310630 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001310630 us-gaap:CommonStockMember 2026-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001310630 us-gaap:RetainedEarningsMember 2026-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001310630 us-gaap:CommonStockMember 2025-06-30 0001310630 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001310630 us-gaap:RetainedEarningsMember 2025-06-30 0001310630 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001310630 2025-06-30 0001310630 CFOO:EliteCreationGroupLimitedMember 2026-01-01 2026-06-30 0001310630 CFOO:AlphaWellnessHKLimitedMember 2026-01-01 2026-06-30 0001310630 CFOO:GuangzhouXiaoXiangHealthIndustryCompanyLimitedMember 2026-01-01 2026-06-30 0001310630 us-gaap:FurnitureAndFixturesMember 2026-06-30 0001310630 us-gaap:VehiclesMember srt:MinimumMember 2026-06-30 0001310630 us-gaap:VehiclesMember srt:MaximumMember 2026-06-30 0001310630 us-gaap:LeaseholdImprovementsMember 2026-06-30 0001310630 CFOO:SalesOfHealthcareProductsMember 2026-04-01 2026-06-30 0001310630 CFOO:SalesOfHealthcareProductsMember 2025-04-01 2025-06-30 0001310630 CFOO:SalesOfHealthcareProductsMember 2026-01-01 2026-06-30 0001310630 CFOO:SalesOfHealthcareProductsMember 2025-01-01 2025-06-30 0001310630 CFOO:SaleOfWineProductsMember 2026-04-01 2026-06-30 0001310630 CFOO:SaleOfWineProductsMember 2025-04-01 2025-06-30 0001310630 CFOO:SaleOfWineProductsMember 2026-01-01 2026-06-30 0001310630 CFOO:SaleOfWineProductsMember 2025-01-01 2025-06-30 0001310630 CFOO:PeriodEndHKUSExchangeRateMember 2026-06-30 0001310630 CFOO:PeriodEndHKUSExchangeRateMember 2025-06-30 0001310630 CFOO:PeriodAverageHKUSExchangeRateMember 2026-06-30 0001310630 CFOO:PeriodAverageHKUSExchangeRateMember 2025-06-30 0001310630 CFOO:PeriodEndRMBUSExchangeRateMember 2026-06-30 0001310630 CFOO:PeriodEndRMBUSExchangeRateMember 2025-06-30 0001310630 CFOO:PeriodAverageRMBUSExchangeRateMember 2026-06-30 0001310630 CFOO:PeriodAverageRMBUSExchangeRateMember 2025-06-30 0001310630 CFOO:HealthcareSegmentMember 2026-04-01 2026-06-30 0001310630 CFOO:WineSegmentMember 2026-04-01 2026-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesOfHealthcareProductsMember 2026-04-01 2026-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesOfHealthcareProductsMember 2026-04-01 2026-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SaleOfWineProductsMember 2026-04-01 2026-06-30 0001310630 CFOO:WineSegmentMember CFOO:SaleOfWineProductsMember 2026-04-01 2026-06-30 0001310630 CFOO:HealthcareSegmentMember 2025-04-01 2025-06-30 0001310630 CFOO:WineSegmentMember 2025-04-01 2025-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesOfHealthcareProductsMember 2025-04-01 2025-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesOfHealthcareProductsMember 2025-04-01 2025-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SaleOfWineProductsMember 2025-04-01 2025-06-30 0001310630 CFOO:WineSegmentMember CFOO:SaleOfWineProductsMember 2025-04-01 2025-06-30 0001310630 CFOO:HealthcareSegmentMember 2026-01-01 2026-06-30 0001310630 CFOO:WineSegmentMember 2026-01-01 2026-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesOfHealthcareProductsMember 2026-01-01 2026-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesOfHealthcareProductsMember 2026-01-01 2026-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SaleOfWineProductsMember 2026-01-01 2026-06-30 0001310630 CFOO:WineSegmentMember CFOO:SaleOfWineProductsMember 2026-01-01 2026-06-30 0001310630 CFOO:HealthcareSegmentMember 2025-01-01 2025-06-30 0001310630 CFOO:WineSegmentMember 2025-01-01 2025-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SalesOfHealthcareProductsMember 2025-01-01 2025-06-30 0001310630 CFOO:WineSegmentMember CFOO:SalesOfHealthcareProductsMember 2025-01-01 2025-06-30 0001310630 CFOO:HealthcareSegmentMember CFOO:SaleOfWineProductsMember 2025-01-01 2025-06-30 0001310630 CFOO:WineSegmentMember CFOO:SaleOfWineProductsMember 2025-01-01 2025-06-30 0001310630 CFOO:WineProductsMember 2026-06-30 0001310630 CFOO:WineProductsMember 2025-12-31 0001310630 CFOO:HealthcareProductsMember 2026-06-30 0001310630 CFOO:HealthcareProductsMember 2025-12-31 0001310630 2025-01-01 2025-12-31 0001310630 country:HK 2026-01-01 2026-06-30 0001310630 CFOO:PRCMember 2026-01-01 2026-06-30 0001310630 country:CN 2026-01-01 2026-06-30 0001310630 country:HK 2025-01-01 2025-06-30 0001310630 CFOO:PRCMember 2025-01-01 2025-06-30 0001310630 country:US 2026-06-30 0001310630 country:US 2025-12-31 0001310630 country:HK 2026-06-30 0001310630 country:HK 2025-12-31 0001310630 country:CN 2026-06-30 0001310630 country:CN 2025-12-31 0001310630 srt:DirectorMember 2026-06-30 0001310630 srt:DirectorMember 2025-12-31 0001310630 us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0001310630 us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0001310630 us-gaap:CustomerConcentrationRiskMember CFOO:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-06-30 0001310630 us-gaap:CustomerConcentrationRiskMember CFOO:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-06-30 0001310630 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember CFOO:CustomersMember 2026-01-01 2026-06-30 0001310630 us-gaap:CustomerConcentrationRiskMember CFOO:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001310630 us-gaap:CustomerConcentrationRiskMember CFOO:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001310630 us-gaap:CustomerConcentrationRiskMember CFOO:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001310630 us-gaap:CustomerConcentrationRiskMember CFOO:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001310630 CFOO:VendorOneMember CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-06-30 0001310630 CFOO:VendorTwoMember CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-06-30 0001310630 CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember CFOO:VendorsMember 2026-01-01 2026-06-30 0001310630 CFOO:VendorOneMember CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember 2025-04-01 2025-06-30 0001310630 CFOO:VendorOneMember CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-06-30 0001310630 CFOO:VendorTwoMember CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember 2025-04-01 2025-06-30 0001310630 CFOO:VendorTwoMember CFOO:TotalPurchasesMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:HKD iso4217:CNY CFOO:Integer CFOO:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2026, or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________to _________

 

001-32522

Commission file number

 

China Foods Holdings Ltd.

(Exact name of registrant as specified in its charter)

 

Delaware   84-1735478

State or other jurisdiction of

incorporation or organization

 

(I.R.S. Employer

Identification No.)

 

Room 2301A, China Resources Building,    
26 Harbour Road,    
Wanchai, Hong Kong   0000
(Address of principal executive offices)   (Zip Code)

 

(852) 3618-8608

Registrant’s telephone number, including area code

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically on its corporate Web site, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. The Registrant’s shares were last sold at a price of $0.66 per share. Although the Registrant’s stock has very few trades and limited volume, based on the last sales price of $0.66 shares held by non-affiliates would have a market value of $863,939.

 

As of August 14, 2026, the Registrant had 20,252,309 shares of common stock issued and outstanding.

 

No documents are incorporated into the text by reference.

 

 

 

 

 

 

Table of Contents

 

   

Page No.

     
  PART I – FINANCIAL INFORMATION  
     
Item 1. Unaudited Condensed Consolidated Financial Statements 3
     
  Notes to Unaudited Condensed Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 22
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 26
     
Item 4. Controls and Procedures 26
     
  PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 27
     
Item 1A. Risk Factors 27
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27
     
Item 3. Defaults Upon Senior Securities 27
     
Item 4. Mine Safety Disclosures 27
     
Item 5. Other Information 27
     
Item 6. Exhibits 27
     
SIGNATURES 28

 

2

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Balance Sheets

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   June 30, 2026   December 31, 2025 
   (Unaudited)   (Audited) 
ASSETS          
Current Assets          
Cash and cash equivalents  $15,923   $9,893 
Prepayments, deposits and other receivables   112,228    108,388 
Inventories, net   40,407    39,255 
Amount due from a director   -    477 
Income tax refundable   5,339    4,930 
Total Current Assets   173,897    162,943 
           
Non-Current Assets          
Plant and equipment, net   24,708    27,860 
Right of use assets, net   15,479    20,425 
Intangible assets, net   1,465    1,662 
Total Non-Current Assets   41,652    49,947 
           
TOTAL ASSETS  $215,549   $212,890 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current Liabilities          
Accrued liabilities and other payables  $30,511   $58,680 
Customer deposits   209,708    204,245 
Lease Liabilities   11,517    10,920 
Amount due to directors   518,245    474,102 
Amount due to a related company   415,509    370,302 
Amount due to related parties   440,331    362,608 
Total Current Liabilities   1,625,821    1,480,857 
           
Non Current Liabilities          
Lease liabilities   3,962    9,504 
Total Liabilities   1,629,783    1,490,361 
           
Stockholders’ (Deficit) Equity          
Common stock $0.0001 par value, 100,000,000 shares authorized, 20,252,309 and 20,252,309 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively   2,025    2,025 
Additional paid-in capital   1,290,355    1,290,355 
Accumulated other comprehensive loss   (51,051)   (39,635)
Accumulated deficit   (2,655,563)   (2,530,216)
Total Stockholders’ Deficit   (1,414,234)   (1,277,471)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $215,549   $212,890 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(Unaudited)

 

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
                 
Revenue, net   2    142,214    255    142,255 
                     
Cost of revenue   -    (126,654)   (24)   (126,670)
                     
Gross profit   2    15,560    231    15,585 
                     
Operating expenses:                    
Selling and distribution expenses   2    30    226    5,112 
General and administrative expenses   63,752    112,885    125,355    211,569 
Total operating expenses   63,754    112,915    125,581    216,681 
                     
Loss from operation   (63,752)   (97,355)   (125,350)   (201,096)
                     
Other Income:                    
Interest income   2    2    3    6 
Sundry income   -    1    -    183 
Total other income   2    3    3    189 
                     
Loss before income tax   (63,750)   (97,352)   (125,347)   (200,907)
                     
Income tax expense   -    -    -    - 
                     
NET LOSS   (63,750)   (97,352)   (125,347)   (200,907)
                     
Other comprehensive loss:                    
Foreign currency adjustment loss   (10,468)   (4,852)   (11,416)   (5,443)
                     
Comprehensive loss   (74,218)   (102,204)   (136,763)   (206,350)
                     
Net loss per common share                    
Basic and diluted  $(0.00)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted average number of common share                    
Basic and diluted   20,252,309    20,252,309    20,252,309    20,252,309 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Statements of Changes in Shareholders’ (Deficit) Equity

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   Share   Amount   capital   deficit   loss   deficit 
   For the three and six months ended June 30, 2026 
               Accumulated     
       Additional       other   Total 
   Common Stock   paid-in   Accumulated   comprehensive   stockholders’ 
   Share   Amount   capital   deficit   loss   deficit 
       $   $   $   $   $ 
                         
Balance at January 1, 2026   20,252,309    2,025    1,290,355    (2,530,216)   (39,635)   (1,277,471)
                               
Net loss for the period   -    -    -    (61,597)   -    (61,597)
                               
Foreign currency translation adjustment   -    -    -    -    (948)   (948)
                               
Balance at March 31, 2026   20,252,309    2,025    1,290,355    (2,591,813)   (40,583)   (1,340,016)
                               
Net loss for the period   -    -    -    (63,750)   -    (63,750)
                               
Foreign currency translation adjustment   -    -    -    -    (10,468)   (10,468)
                               
Balance at June 30, 2026   20,252,309    2,025    1,290,355    (2,655,563)   (51,051)   (1,414,234)

 

   For the three and six months ended June 30, 2025 
               Accumulated     
       Additional       other   Total 
   Common Stock   paid-in   Accumulated   comprehensive   stockholders’ 
   Share   Amount   capital   deficit   loss   deficit 
       $   $   $   $   $ 
                         
Balance at January 1, 2025   20,252,309    2,025    1,290,355    (2,131,544)   (11,643)   (850,807)
                               
Net loss for the period   -    -    -    (103,555)   -    (103,555)
                               
Foreign currency translation adjustment   -    -    -    -    (591)   (591)
                               
Balance at March 31, 2025   20,252,309    2,025    1,290,355    (2,235,099)   (12,234)   (954,953)
                               
Net loss for the period   -    -    -    (97,352)   -    (97,352)
                               
Foreign currency translation adjustment   -    -    -    -    (4,852)   (4,852)
                               
Balance at June 30, 2025   20,252,309    2,025    1,290,355    (2,332,451)   (17,086)   (1,057,157)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Statements of Cash Flows

(Currency expressed in United States Dollars (“US$”))

 

   2025   2025 
   Six months ended June 30, 
   2026   2025 
Cash flows from operating activities:          
Net loss  $(125,347)  $(200,907)
Adjustments to reconcile net loss to net cash used in operating activities          
Depreciation of plant and equipment   3,504    3,489 
Depreciation of right of use asset   

5,513

    - 
Amortization of intangible assets   245    232 
Non-cash lease expense   441    - 
Adjustments to reconcile net loss to net cash used in operating activities, Total   (115,644)   (197,186)
Change in operating assets and liabilities:          
Accounts receivables   -    - 
Prepayments, deposits and other receivables   (3,840)   157,061 
Inventories   (1,152)   (43,295)
Accounts payable   -    - 
Accrued liabilities and other payables   (28,169)   1,500 
Customer deposits   5,463    (96,118)
Lease liabilities   (5,954)   - 
Income tax refundable   (409)   (8,575)
Net cash used in operating activities   (149,705)   (186,613)
           
Cash flows from investing activities:          
Purchase of plant and equipment   -    - 
Net cash used in investing activities   -    - 
           
Cash flows from financing activities:          
Advance from related parties   78,200    106,040 
Advance from directors   44,143    96,082 
Advance from a related company   45,207    14,427 
Net cash provided by financing activities   167,550    216,549 
           
Foreign currency translation adjustment   (11,815)   (5,559)
           
Net change in cash and cash equivalents   6,030    24,377 
           
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD   9,893    39,192 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $15,923   $63,569 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

China Foods Holdings Ltd.

Notes to Unaudited Condensed Consolidated Financial Statements

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

NOTE 1 – NATURE OF OPERATIONS

 

China Foods Holdings Ltd. (the “Company” or “CFOO”) was incorporated in Delaware on January 10, 2019.

 

The Company is a health and wellness company that develops, markets, promotes and distributes a variety of customized health and wellness care products and services, including supplements, healthy snacks, meal replacements, skincare products, and nutritional consultation services to consumers in China. The Company works with certain licensed healthcare food factories to develop and manufacture products and services that are distributed conventionally through sales agents and also through a network of e-commerce and social media platforms.

 

The following table depicts the description of the Company’s subsidiaries:

 

Name   Place of incorporation and kind of legal entity   Principal activities   Particulars of registered/ paid up share capital   Effective interest held  
                   
Elite Creation Group Limited   BVI, a limited liability company   Investment holding   50,000 issued shares of US$1each     100 %
                     
Alpha Wellness (HK) Limited   Hong Kong, a limited liability company   Investment holding   300,000 issued shares for HK$300,000     100 %
                     
Guangzhou Xiao Xiang Health Industry Company Limited   The PRC, a limited liability company   Sales of healthcare products   RMB 9,000,000     100 %

 

The Company and its subsidiaries are hereinafter referred to as (the “Company”).

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation and consolidation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting, and in accordance with instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements contained in this report reflect all adjustments that are normal and recurring in nature and considered necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The year-end balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The results of operations for the interim period are not necessarily indicative of the results expected for the full year. These unaudited condensed consolidated financial statements, footnote disclosures and other information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on April 15, 2026.

 

7

 

 

The unaudited condensed consolidated financial statements are presented in US Dollars and include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

 

Use of estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Significant areas for which management uses estimates include:

 

inventory;
   
estimated lives for tangible and intangible assets; and
   
valuation allowance for deferred tax asset

 

These estimates require the use of judgment as future events and the effect of these events cannot be predicted with certainty. The estimates will change as new events occur, as more experience is acquired and as more information is obtained. We evaluate and update our assumptions and estimates on an ongoing basis and we may consult outside experts to assist as considered necessary.

 

Segment Reporting

 

Accounting Standards Codification (“ASC”) Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in consolidated financial statements. Currently, the Company operates in two reportable operating segments in Hong Kong and China.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

 

Accounts receivable

 

Accounts receivable are recorded at the invoiced amount and do not bear interest, which are due within contractual payment terms, generally 30 to 90 days from completion of service. Credit is extended based on evaluation of a customer’s financial condition, the customer credit-worthiness and their payment history. Accounts receivable outstanding longer than the contractual payment terms are considered past due. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. At the end of the fiscal year, the Company specifically evaluates individual customer’s financial condition, credit history, and the current economic conditions to monitor the progress of the collection of accounts receivables. The Company will consider the allowance for doubtful accounts for any estimated losses resulting from the inability of its customers to make required payments. For the receivables that are past due or not being paid according to payment terms, the appropriate actions are taken to exhaust all means of collection, including seeking legal resolution in a court of law. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers. As of June 30, 2026 and December 31, 2025, there was no allowance for doubtful accounts.

 

Allowance for Expected Credit Losses

 

In accordance with ASC Topic 326, “Credit Losses – Measurement of Credit Losses on Financial Instruments” (ASC 326), the Company utilizes the current expected credit losses (“CECL”) model to determine an allowance that reflects its best estimate of the expected credit losses on accounts receivable, prepayments, deposits and other receivables which is recorded as a liability to offset the receivables. The CECL model is prepared after considering historical experience, current conditions, and reasonable and supportable economic forecasts to estimate expected credit losses. Accounts receivable, prepayments, deposits and other receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense.

 

As of June 30, 2026 and December 31, 2025, there was no allowance for expected credit losses.

 

Inventories

 

Inventories are stated at the lower of cost or market value (net realizable value), cost being determined on a first-in, first-out method. Costs include material and manufacturing overhead costs. The Company provides inventory allowances based on excess and obsolete inventories determined principally by customer demand. As of June 30, 2026 and December 31, 2025, the Company did not record an allowance for obsolete inventories, nor have there been any write-offs.

 

8

 

 

Plant and equipment

 

Plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis over the following expected useful lives from the date on which they become fully operational and after taking into account their estimated residual values:

 

    Expected useful lives   Residual value  
Furniture, fixture and equipment   3 years     5 %
Motor vehicle   3 to 4 years     5%-10 %
Leasehold improvement   2 years     5 %

 

Expenditures for repairs and maintenance are expensed as incurred. When assets have been retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in the results of operations.

 

Depreciation expense for the three and six months ended June 30, 2026, were $1,752 and $3,504, respectively, and for the three and six months ended June 30, 2025, were $1,742 and $3,489, respectively.

 

Intangible assets

 

Intangible assets represented trademarks of their products and are stated at cost less accumulated amortization and any recognized impairment loss.

 

Amortization is provided over the term of their registrations on a straight-line basis, which is 10 years and will expire in 2028 and 2029.

 

Amortization expense for the three and six months ended June 30, 2026, were $123 and $245, respectively, and for the three and six months ended June 30, 2025, were $116 and $232, respectively.

 

Impairment of long-lived assets

 

In accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as plant and equipment, as well as intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. There has been no impairment charge for the periods presented.

 

Revenue recognition

 

The Company adopted Accounting Standards Codification (“ASC”) 606 – “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, a performance obligation is a promise within a contract to transfer a distinct good or service, or a series of distinct goods and services, to a customer. Revenue is recognized when performance obligations are satisfied and the customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services. Under the standard, a contract’s transaction price is allocated to each distinct performance obligation. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps:

 

  identify the contract with a customer;
     
  identify the performance obligations in the contract;
     
  determine the transaction price;
     
  allocate the transaction price to performance obligations in the contract; and
     
  recognize revenue as the performance obligation is satisfied.

 

9

 

 

Currently, the Company operates two business segments.

 

Healthcare Business mainly provides health consulting advisory services and healthcare and wellness products to customers.

 

Revenue is earned from the rendering of health consulting advisory services to customers. The Company recognizes services revenue over the period in which such services are performed. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

 

The sale and distribution of healthcare products, such as (i) Nutrition Catering (ii) Special Health Food (iii) Health Supplement and (iv) Skincare, is the only performance obligation under the fixed-fee arrangements. Revenue is recognized when control of healthcare products transfers to the customer, typically upon delivery, if that is the point at which the performance obligation is satisfied. The Company records its revenues, net of value added taxes (“VAT”) on the majority of the products at the rate of 13% on the invoiced value of sales. The cost, such as shipping cost and material cost, is recognized when the product is delivered to customers. The Company records its cost including taxes.

 

Wine Business mainly provides wine products to customers. Revenue is recognized from the sale of wine products upon delivery to customers, when the title and risk of loss are fully transferred to customers. The Company records its revenues, net of value added taxes (“VAT”) on the majority of the products at the rate of 13% on the invoiced value of sales. The cost, such as shipping cost and material cost, is recognized when the product is delivered to customers. The Company records its cost including taxes.

 

Disaggregation of Revenue

 

The following table provides information about disaggregated revenue from customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments.

 

 

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
                 
Sales of healthcare products  $-   $142,130   $77   $142,171 
Sales of wine products   2    84    178    84 
                     
TOTAL  $2   $142,214   $255   $142,255 

 

10

 

 

Income taxes

 

The Company adopted the ASC Topic 740, “Income Taxes” (“ASC Topic 740”) provisions of paragraph 740-10-25-13, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the condensed consolidated financial statements. Under paragraph 740-10-25-13, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Paragraph 740-10-25-13 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of paragraph 740-10-25-13.

 

The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary.

 

Foreign currencies translation

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the unaudited condensed consolidated statement of operations.

 

The reporting currency of the Company is United States Dollar (“US$”) and the accompanying unaudited condensed consolidated financial statements have been expressed in US$. In addition, the Company is operating in Hong Kong SAR and the PRC and maintains its books and record in its local currency, Hong Kong Dollars (“HK$”) and Renminbi (“RMB”), which is a functional currency as being the primary currency of the economic environment in which its operations are conducted. In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the year. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income within the statements of changes in shareholders’ equity.

 

Translation of amounts from HK$ and RMB into US$ has been made at the following exchange rates for the six months ended June 30, 2026, and 2025:

 

   2026   2025 
Period-end HK$:US$ exchange rate   0.12751    0.12738 
Period average HK$:US$ exchange rate   0.12770    0.12822 
Period-end RMB:US$ exchange rate   0.14711    0.13941 
Period average RMB:US$ exchange rate   0.14593    0.13809 

 

Net loss per share

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share”. Basic (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted (loss) income per share is computed similar to basic (loss) income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Potential common stocks that have an anti-dilutive effect (i.e. those that increase income per share or decrease loss per share) are excluded from the calculation of diluted earnings per share.

 

11

 

 

Comprehensive income

 

ASC Topic 220, “Comprehensive Income”, establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying condensed consolidated statements of changes in stockholders’ equity, consists of changes in unrealized gains and losses on foreign currency translation. This comprehensive income is not included in the computation of income tax expense or benefit.

 

Retirement plan costs

 

Contributions to retirement plans (which are defined contribution plans) are charged to general and administrative expenses in the accompanying statements of operation as the related employee service are provided.

 

Leases

 

The Company adopts the FASB Accounting Standards Update (“ASU”) 2016-02 “Leases (Topic 842)” for all periods presented. This standard requires lessees to recognize lease assets (“right of use”) and related lease obligations (“lease liabilities”) on the balance sheet for leases with terms in excess of 12 months.

 

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the consolidated balance sheets. Finance leases are included in finance lease ROU assets and finance lease liabilities in the consolidated balance sheets.

 

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease and finance lease ROU assets and liabilities are recognized, based on the present value of lease payments over the lease term discounted using the rate implicit in the lease. In cases where the implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

Related parties

 

The Company follows the ASC Topic 850-10, “Related Party” for the identification of related parties and disclosure of related party transactions.

 

Pursuant to section 850-10-20 the related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and income-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

12

 

 

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amount due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

Commitments and contingencies

 

The Company follows the ASC Topic 450-20, “Commitments” to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

 

Fair value Measurement

 

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and has adopted paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 of the FASB Accounting Standards Codification establishes a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, paragraph 820-10-35-37 of the FASB Accounting Standards Codification establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by paragraph 820-10-35-37 of the FASB Accounting Standards Codification are described below:

 

  Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
     
  Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
     
  Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data.

 

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

 

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, accounts receivable, deposits and other receivables, accounts payable, accrued liabilities and other payables, and customer deposits approximate their fair values because of the short maturity of these instruments.

 

13

 

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

 

Accounting Standards Recently Adopted

 

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related earnings per share guidance. This standard became effective for the Company beginning on January 1, 2022. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted this guidance effective January 1, 2022, and the adoption of this standard did not have a material impact on its consolidated financial statements.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This ASU clarifies the accounting for modifications or exchanges of freestanding equity-classified written call options (i.e. warrants) so that the transaction should be treated as an exchange of the original instrument for a new instrument. This standard is effective for fiscal years beginning after December 15, 2021, on a prospective basis, with early adoption permitted. The Company adopted this guidance effective January 1, 2022, and the adoption of this standard did not have a material impact on its consolidated financial statements.

 

In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. This ASU defers the sunset date of Topic 848, which provides relief to entities affected by reference rate reform. The ASU defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2025. The standard is effective immediately and the Company adopted the standard in December 2022 with no financial impact. The Company is currently assessing the impact ASU 2020-04, for which this ASU 2022-06 relates, will have on its consolidated financial statements.

 

In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements. This ASU clarifies the accounting for leasehold improvements associated with common control leases and allows lessees to amortize improvements over the useful life if certain criteria are met. The standard is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company early adopted ASU 2023-01 in 2023. The adoption did not have a material impact on the Company’s consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to enhance the transparency and decision-usefulness of segment information. This ASU requires disclosure of significant segment expenses regularly reviewed by the chief operating decision maker (CODM). The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact of this ASU on its segment disclosure but does not expect it to have a material effect on the consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid. The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently assessing the potential impact of the adoption of this standard on its disclosures.

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

 

NOTE 3 – LIQUIDITY AND GOING CONCERN

 

The Company’s cash balance as of June 30, 2026, was $15,923, as compared to $9,893 as of December 31, 2025, it was increased by $6,030. The current liabilities exceeded current assets by $1,451,924, the Company had an accumulated deficit of $2,655,563. The Company has assessed its ability to continue as a going concern for the 12 months following the issuance of these financial statements. Based on this assessment, management has concluded that the going concern basis of accounting remains appropriate.

 

The Company continued to operate and fulfill contractual obligations during the period and has received substantial customer payments and has ongoing signed contracts that are expected to result in revenue recognition in the near future, supporting the continuity of its business operations.

 

Furthermore, the Company has entered into legally binding, unconditional, and enforceable agreements with its controlling shareholder to provide financial support sufficient to meet all obligations as they fall due for at least the next 12 months. The shareholder has a demonstrated history of providing such support, including capital injections and shareholder loans in recent periods. Management’s liquidity forecasts indicate that the Company will have sufficient resources to fund its operations without reliance on external financing.

 

Accordingly, management has concluded that there is no substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the date of issuance of these financial statements.

 

14

 

 

NOTE 4 – SEGMENT REPORTING

 

Currently, the Company has two reportable business segments:

 

(i) Healthcare Segment, mainly provides health consulting advisory services and healthcare and wellness products to its customers; and
   
(ii) Wine Segment, mainly provides wine products to its customers.

 

In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments.

 

   Healthcare Segment   Wine Segment   Total 
   Three months ended June 30, 2026 
   Healthcare Segment   Wine Segment   Total 
Revenue from external customers:               
Sale of healthcare products  $-   $-   $- 
Sale of wine products   -    2    2 
Total revenue   -    2    2 
                
Cost of revenue:               
Sale of healthcare products   -    -    - 
Sale of wine products   -    -    - 
Total cost of revenue   -    -    - 
                
Gross profit   -    2    2 
                
Operating expenses:               
Selling and distribution   -    (2)   (2)
General and administrative   (12,750)   (51,002)   (63,752)
Total operating expenses   (12,750)   (51,004)   (63,754)
                
Segment loss  $(12,750)  $(51,002)  $(63,752)

 

   Healthcare Segment   Wine Segment   Total 
   Three months ended 30 June, 2025 
   Healthcare Segment   Wine Segment   Total 
Revenue from external customers:               
Sale of healthcare products  $142,130   $-   $142,130 
Sale of wine products   -    84    84 
Total revenue   142,130    84    142,214 
                
Cost of revenue:               
Sale of healthcare products   (126,649)   -    (126,649)
Sale of wine products   -    (5)   (5)
Total cost of revenue   (126,649)   (5)   (126,654)
                
Gross profit   15,481    79    15,560 
                
Operating expenses:               
Selling and distribution   (30)   -    (30)
General and administrative   (22,577)   (90,308)   (112,885)
Total operating expenses   (22,607)   (90,308)   (112,915)
                
Segment loss  $(7,126)  $(90,229)  $(97,355)

 

15

 

 

   Healthcare Segment   Wine Segment   Total 
   Six months ended June 30, 2026 
   Healthcare Segment   Wine Segment   Total 
Revenue from external customers:               
Sale of healthcare products  $77   $-   $77 
Sale of wine products   -    178    178 
Total revenue   77    178    255 
                
Cost of revenue:               
Sale of healthcare products   (14)   -    (14)
Sale of wine products   -    (10)   (10)
Total cost of revenue   (14)   (10)   (24)
                
Gross profit   63    168    231 
                
Operating Expenses               
Selling and distribution   (45)   (181)   (226)
General and administrative   (25,071)   (100,284)   (125,355)
Total operating expenses   (25,116)   (100,465)   (125,581)
                
Segment loss  $(25,053)  $(100,297)  $(125,350)

 

   Healthcare Segment   Wine Segment   Total 
   Six months ended June 30, 2025 
   Healthcare Segment   Wine Segment   Total 
Revenue from external customers:               
Sale of healthcare products   142,171   $-   $142,171 
Sale of wine products   -    84    84 
Total revenue   142,171    84    142,255 
                
Cost of revenue:               
Sale of healthcare products   (126,665)   -    (126,665)
Sale of wine products   -    (5)   (5)
Total cost of revenue   (126,665)   (5)   (126,670)
                
Gross profit   15,506    79    15,585 
                
Operating Expenses               
Selling and distribution   (1,022)   (4,090)   (5,112)
General and administrative   (42,314)   (169,255)   (211,569)
Total operating expenses   (43,336)   (173,345)   (216,681)
                
Segment loss  $(27,830)  $(173,266)  $(201,096)

 

The revenues are based on the countries in which the customer is located. For the three and six months ended June 30, 2026, and 2025, all revenues reported are derived from customers located in China.

 

NOTE 5 – PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

 

Prepayment, deposits and other receivables consisted of the following:

 

   June 30, 2026   December 31, 2025 
       (Audited) 
Prepayments  $83,462   $81,672 
Purchase deposits   14,792    14,322 
Rental and utility deposits   10,990    10,925 
Other receivables   2,984    1,469 
Prepayments Deposits and other receivables  $112,228   $108,388 

 

Purchase deposits represented deposit payments made to vendors for procurement, which are interest-free, unsecured and relieved against accounts payable when goods are received by the Company.

 

16

 

 

NOTE 6 – INVENTORIES

 

Inventories consisted of the following:

 

   June 30, 2026   December 31, 2025 
       (Audited) 
Finished goods – Wine products  $13,476   $13,094 
Finished goods – Healthcare products   26,931    26,161 
Inventories, net  $40,407   $39,255 

 

For the six months ended June 30, 2026, and year ended December 2025, no allowance for obsolete inventories was recorded by the Company.

 

NOTE 7 – PLANT AND EQUIPMENT

  

   June 30, 2026   December 31, 2025 
       (Audited) 
Motor vehicle  $300,841   $291,197 
Furniture, fixture and equipment   15,630    15,023 
Foreign translation difference, net   7,102    10,251 
Plant and equipment, gross   323,573    316,471 
           
Less: accumulated depreciation   (292,115)   (278,944)
Foreign translation difference, net   (6,750)   (9,667)
Plant and equipment. net  $24,708   $27,860 

 

Depreciation expenses for the six months ended June 30, 2026 and 2025 were $3,504 and $3,489, respectively.

 

NOTE 8 – CUSTOMER DEPOSITS

 

Customer deposits represented cash paid to the Company from the customers, for which the Company has an obligation to deliver the orders to satisfy with the customers, or to return the funds, within twelve months.

 

As of June 30, 2026, and December 31, 2025, the deposit received from customers was $209,708 and $204,245, respectively.

 

NOTE 9 – AMOUNTS DUE TO DIRECTORS AND A RELATED COMPANY

 

The amounts represented temporary advances to the Company by its directors and its related company which were unsecured, interest-free and had no fixed terms of repayments.

 

NOTE 10 – LEASE

 

The Company leased warehouse facilities under non-cancelable operating leases with a lease term of two years. Pursuant to the terms of the lease agreements, the Company may apply for renewal three months prior to the expiry of the lease term, subject to the Landlord’s consent. The Landlord has agreed to refund the security deposit upon termination of the leases, provided that the original deposit receipt is returned.

 

Right of use assets and lease liability – right of use are as follows:

 

   June 30, 2026   December 31, 2025 
       (Audited) 
Right-of-use assets  $15,479   $20,425 

 

The lease liability is as follows:

 

   June 30, 2026   December 31, 2025 
       (Audited) 
Current portion  $11,517   $10,920 
Non-current portion   3,962    9,504 
           
Total  $15,479   $20,424 
Total lease liability  $15,479   $20,424 

 

The future minimum lease payment schedule as follows:

For the year ended June 30,  Amount 
2027  $11,517 
2028   3,962 
Total operating lease liabilities  $15,479 

 

17

 

 

NOTE 11 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company is authorized, subject to limitations prescribed by Delaware law, to issue up to 100,000,000 shares of common stock with a par value of $0.0001.

 

Dividend Rights

 

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.

 

Voting Rights

 

Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Under our Certificate of Incorporation, stockholders do not have the right to cumulate votes for the election of directors.

 

No Preemptive or Similar Rights

 

Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

 

Right to Receive Liquidation Distributions

 

Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

As of June 30, 2026, and December 31, 2025, a total of 20,252,309 and 20,252,309 outstanding shares of common stock were issued, respectively.

 

Preferred Stock

 

The Company is not currently authorized to issue shares of preferred stock. The Certificate of Incorporation, however, allows the board of directors to authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock in the event that shares of preferred stock are authorized in the future. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of the Company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. The Company has no current plans to issue any shares of preferred stock.

 

NOTE 12 – NET LOSS PER SHARE

 

Basic net loss per share is computed using the weighted average number of common shares outstanding during the year. The dilutive effect of potential common shares outstanding is included in diluted net loss per share. The following table sets forth the computation of basic and diluted net loss per share for the six months ended June 30, 2026 and 2025.

 

   2026   2025 
   Six months ended June 30, 
   2026   2025 
Net loss attributable to common shareholders  $(125,347)  $(200,907)
           
Weighted average common shares outstanding – Basic and diluted   20,252,309    20,252,309 
           
Net loss per share – Basic and diluted  $(0.01)  $(0.01)

 

For the six months ended June 30, 2026 and 2025, diluted weighted-average common shares outstanding is equal to basic weighted-average common shares, due to the Company’s net loss position. Hence, no common stock equivalents were included in the computation of diluted net loss per share since such inclusion would have been antidilutive.

 

NOTE 13 – INCOME TAXES

 

The provision for income taxes consisted of the following:

 

    2026     2025  
    Six months ended June 30,  
    2026     2025  
             
Current tax   $ -     $ -  
Deferred tax     -       -  
Income tax expense   $ -     $ -  

 

The Company mainly operates in the PRC that is subject to taxes in the governing jurisdictions in which it operates. The effective tax rate in the years presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates, as follows:

 

18

 

 

United States of America

 

CFOO is registered in the State of Delaware and is subject to US federal corporate income tax. The U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”) significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. The Company’s policy is to recognize accrued interest and penalties related to unrecognized tax benefits in its income tax provision. The Company has not accrued or paid interest or penalties which were not material to its results of operations for the years presented.

 

For the six months ended June 30, 2026 and 2025 the income tax expense was $0 and $0, respectively. As of June 30, 2026, and December 31, 2025, the Company has not accrued any penalties on uncertain tax positions.

 

As of June 30, 2026, the operation in the United States incurred $192,732 of cumulative net operating losses which can be carried forward indefinitely to offset future taxable income.

 

BVI

 

ECGL is incorporated in the British Virgin Islands and is not subject to taxation. In addition, upon payments of dividends by these entities to their shareholder, no British Virgin Islands withholding tax will be imposed.

 

Hong Kong

 

The Company’s subsidiary operating in Hong Kong is subject to the Hong Kong Profits Tax at the two-tiered profits tax rates from 8.25% to 16.5% on the estimated assessable profits arising in Hong Kong during the current year, after deducting a tax concession for the tax year. The reconciliation of income tax rate to the effective income tax rate for the six months ended June 30, 2026, and 2025 is as follows:

 

   2026   2025 
   Six months ended June 30, 
   2026   2025 
         
Loss before income tax  $(37,634)  $(94,235)
Statutory income tax rate   8.25%   8.25%
Income tax expense at statutory rate   (3,105)   (7,774)
Tax adjustments   -    - 
Net operating loss   3,105    7,774 
Income tax expense  $-   $- 

 

The PRC

 

The Company’s subsidiary operating in the PRC is subject to the Corporate Income Tax Law of the PRC at a unified income tax rate of 25%. The reconciliation of income tax rate to the effective income tax rate for the six months ended June 30, 2026 and 2025is as follows:

 

   2026   2025 
   Six months ended June 30, 
   2026   2025 
         
Loss before income taxes  $(70,060)  $(93,326)
Statutory income tax rate   25%   25%
Income tax expense at statutory rate   (17,515)   (23,082)
Net operating loss   17,515    23,082 
Income tax expense  $-   $- 

 

19

 

 

The following table sets forth the significant components of the deferred tax assets of the Company as of June 30, 2026 and December 31, 2025

 

   June 30, 2026   December 31, 2025 
       (Audited) 
Deferred tax assets:          
Net operating loss carryforwards          
- United States  $192,732    189,025 
- Hong Kong   45,721    42,616 
- PRC   465,567    448,052 
Net operating loss carryforwards   704,020    679,693 
Less: valuation allowance   (704,020)   (679,693)
Deferred tax assets, net  $-   $- 

 

The Company recognizes interest and penalties, if applicable, related to uncertain tax positions in the income tax provision. There were no reserves for unrecognized tax benefits and no accrued interest related to uncertain tax positions as of June 30, 2026, and December 31, 2025.

 

The Company files income tax returns in U.S. federal, U.S. state and foreign jurisdictions. With some exceptions, most tax years remain open to examination by the taxing authorities due to the Company’s NOL carryforwards.

 

NOTE 14 – RELATED PARTY TRANSACTIONS

 

From time to time, the Company’s director and related company advanced funds to the Company for working capital purpose. Those advances are unsecured, non-interest bearing and due on demand. As of June 30, 2026, and December 31, 2025, the Company owed the balance of $518,245 and $474,102 to its directors, owed the balance of $415,509 and $370,302 to a related company, and owed the balance of $440,331 and $362,608 to a related party.

 

Apart from the transactions and balances detailed elsewhere in these accompanying unaudited condensed consolidated financial statements, the Company has no other significant or material related party transactions during the periods presented.

 

20

 

 

NOTE 15 – CONCENTRATIONS OF RISK

 

The Company is exposed to the following concentrations of risk:

 

(a) Major customers

 

For the three months ended June 30, 2026, there is no single customer who accounted for 10% of more of the Company’s revenues. For the six months ended June 30, 2026, two customers accounted for approximately 30% and 70 % of the Company’s revenues, total amounting to $255.

 

For both the three and six months ended June 30, 2025, two customers accounted for approximately 51% and 49 % of the Company’s revenues, amounting to $72,586 and $69,460, respectively. 

 

All the Company’s customers are located in the PRC.

 

(b) Major vendors

 

For the three months ended June 30, 2026, there is no single vendor who accounted for 10% of more of the Company’s purchases. For the six months ended June 30, 2026, two vendors accounted for approximately 58% and 42 % of the Company’s purchases, total amounting to $24.

 

For the three and six months ended June 30, 2025, two vendors accounted for approximately 77% and 14% of the Company’s total purchases, amounting to $97,508 and $17,843, respectively.

 

All the Company’s vendors are located in the PRC.

 

(c) Credit risk

 

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

(d) Economic and political risk

 

The Company’s major operations are conducted in the PRC. Accordingly, the political, economic, and legal environments in the PRC, as well as the general state of the PRC’s economy may influence the Company’s business, financial condition, and results of operations.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RMB converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

NOTE 16 - COMMITMENTS AND CONTINGENCIES

 

As of June 30, 2026, the Company has no material commitments or contingencies.

 

NOTE 17 - SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before unaudited condensed consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after June 30, 2026 up through the date the Company issued the unaudited condensed consolidated financial statements. During this period, the Company did not have any material recognizable subsequent events.

 

21

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This periodic report contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”) with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management. Statements in this periodic report that are not historical facts are hereby identified as forward-looking statements. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Interim Report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Reform Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

 

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest; changes in U.S., global or regional economic conditions; changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments; increased competitive pressures, both domestically and internationally; legal and regulatory developments, such as regulatory actions affecting environmental activities; the imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls; adverse weather conditions or natural disasters, such as hurricanes and earthquakes; and labor disputes, which may lead to increased costs or disruption of operations.

 

This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive.

 

Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

 

Business Overview

 

We are a health and wellness company that develops, markets, promotes and distributes a variety of customized health and wellness care products and services, including supplements, healthy snacks, meal replacements, skincare products, and nutritional consultation services to consumers in China and Hong Kong. We work with certain licensed healthcare food factories to develop and manufacture products and services that are distributed conventionally through sales agents and also through a network of e-commerce and social media platforms.

 

In addition to products, we are committed to providing customized science-based wellness consultation and service programs to customers. Our diverse products and services target health-conscious customers and differentiate based upon age and gender and seek to manage different conditions. We reach out to customers fitting certain health and lifestyle profiles through our offline and online consultation services, and track eating habits and health indicators to provide customized products such as supplements. We believe this will facilitate the ability of customers to monitor, understand and adjust their health practices and lifestyle anytime and anywhere for increased customer engagement and retention.

 

While recent trade tensions and high tariffs pose potential risks to our supply chain and pricing, we are actively monitoring the situation and implementing strategies such as supplier diversification, local sourcing, and logistics optimization to mitigate these impacts. Committed to innovation and customer well-being, we strive to provide holistic, accessible, and customized wellness solutions that empower our customers to lead healthier lives despite the evolving global trade environment.

 

We conduct our business through our wholly owned subsidiary Guangzhou Xiao Xiang Health Industry Company Limited, a limited liability company organized under the laws of China on March 8, 2017, and Alpha Wellness (HK) Limited, a limited liability company organized under the laws of Hong Kong on April 24, 2019. Elite Creation Group, a limited liability company formed under the laws of the British Virgin Islands formed on September 5, 2018, is holding companies without operations.

 

22

 

 

RESULTS OF OPERATIONS

 

The following table sets forth certain operational data for the three and six months ended June 30, 2026, and 2025:

 

   Three Months Ended   Three Months Ended 
   June 30, 2026   June 30, 2025 
Revenue, net  $                                   2   $                        142,214 
Cost of revenue   -    (126,654)
Gross profit   2    15,560 
Total operating expenses   (63,754)   (112,915)
Total other income   2    3 
Loss before income tax   (63,750)   (97,352)
Income tax expense   -    - 
Net loss   (63,750)   (97,352)

 

   Six Months Ended   Six Months Ended 
   June 30, 2026   June 30, 2025 
Revenue, net  $255   $142,255 
Cost of revenue   (24)   (126,670)
Gross profit   231    15,585 
Total operating expenses   (125,581)   (216,681)
Total other income   3    189 
Loss before income tax   (125,347)   (200,907)
Income tax expense   -    - 
Net loss   (125,347)   (200,907)

 

Revenue. For the three and six months ended June 30, 2026, we generated revenues of $2 and $255, respectively. For the comparative three and six months ended June 30, 2025, we generated revenues of $142,214 and $142,255, respectively. There was a significant decrease in revenue because of a reducing demand in healthcare products during the period.

 

Cost of Revenue. For the three and six months ended June 30, 2026, the cost of revenue was $0 and $24, respectively, and as a percentage of net revenue, approximately 0% and 9%, Cost of revenue for the three and six months ended June 30, 2025, was $126,654 and $126,670, respectively, and as a percentage of net revenue, approximately 89% and 89%, respectively. The decrease in cost of revenue was in line with the drop in revenue during the period.

 

Gross Profit. For the three months ended June 30, 2026, and 2025, the gross profit was $2 and $15,560, respectively, the gross profit margin was 100% and 11%, respectively. For the six months ended June 30, 2026, and 2025, the gross profit was $231 and $15,585, respectively, the gross profit margin was 90% and 11%, respectively.The decrease in gross profit amount was due to lower sales volumes during the period. Cost of revenue decreased in step with reduced sales activity, as direct manufacturing and product costs were aligned with current demand levels. Consequently, cost of revenue was nominal for the three and six months ended June 30, 2026, resulting in gross margins of 100.0% and 90%, respectively.

 

23

 

 

Operating Expenses. For the three and six months ended June 30, 2026, the operating cost was $63,754 and $125,581, respectively, and while for the three and six months ended June 30, 2025, was $112,915 and $216,681, respectively. The operating expenses decreased due to a decrease in selling expenses and better control in administrative expenses.

 

Other Income. For the three and six months ended June 30, 2026, the total other income was $2 and $3, respectively and for the three and six months ended June 30, 2025 was $3 and $189, respectively. Other income decreased due to a decrease in receipt of bank interest income.

 

Net Loss. For the three and six months ended June 30, 2026, we incurred a net loss of $63,750 and $125,347, respectively and for the three and six months ended June 30, 2025, we incurred a net loss of $97,352 and $200,907, respectively. The decrease in net loss was primarily attributable to the significant decrease in administrative expenses.

 

Liquidity and Capital Resources

 

As of June 30, 2026, we had cash and cash equivalents of $15,923.

 

As of December 31, 2025, we had cash and cash equivalents of $9,893.

 

We believe that our current cash and other sources of liquidity discussed below are adequate to support general operations for at least the next 12 months.

 

   Six Months Ended June 30, 
   2026   2025 
Net cash used in operating activities  $(149,705)  $(186,613)
Net cash used in investing activities   -    - 
Net cash provided by financing activities   167,550    216,549 

 

Operating Activities.

 

For the six months ended June 30, 2026, net cash used in operating activities was $149,705 which primarily consisted of a net loss of $125,347, non-cash adjustments of depreciation of plant and equipment of $3,504, non-cash adjustments of depreciation of right of use assets of $5,513, amortization of intangible asset of $245, non-cash lease expense of $441, increase in deposits and other receivables of $3,840, increase in inventories of $1,152, decrease in accrued liabilities and other payables of $28,169, increase in customer deposits of $5,463, decrease in lease liabilities of $5,954 and increase in income tax refundable of $409.

 

For the six months ended June 30, 2025, net cash used in operating activities was $186,613 which primarily consisted of a net loss of $200,907, non-cash adjustments of depreciation of plant and equipment of $3,489, amortization of intangible asset of $232, decrease in deposits and other receivables of $157,061, increase in inventories of $43,295, increase in accrued liabilities and other payables of $1,500, decrease in customer deposits of $96,118 and increase in income tax refundable of $8,575.

 

We expect to continue to rely on cash generated through financing from our existing stockholders and private placements of our securities, however, to finance our operations and future acquisitions.

 

Investing Activities.

 

For the six months ended June 30, 2026, and 2025, net cash used in investing activities was $0 and $0, which was movement during the period.

 

Financing Activities.

 

For the six months ended June 30, 2026, and 2025, net cash provided by financing activities was $167,550 and $216,549, which primarily consisted of advances from a director, related parties and a related company.

 

24

 

 

Off Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements, and it is not anticipated that the Company will enter into any off-balance sheet arrangements.

 

Critical Accounting Policies, Judgments and Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the presentation of our financial condition and results of operations and require management’s subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe the following accounting policies are critical in the preparation of our financial statements.

 

The Company’s accounting policies are more fully described in Note 1 and 2 of the unaudited condensed consolidated financial statements. As discussed in Note 1 and 2, the preparation of the unaudited condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about the future events that affect the amounts reported in the financial statements and the accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual differences could differ from these estimates under different assumptions or conditions. The Company believes that the following addresses the Company’s most critical accounting policies.

 

Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets will be reflected on the balance sheet when it is determined that it is more likely than not that the asset will be realized. A valuation allowance has currently been recorded to reduce our deferred tax assets to $0.

 

Forward-looking Statements

 

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Reform Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

 

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest; changes in U.S., global or regional economic conditions; changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments; increased competitive pressures, both domestically and internationally; legal and regulatory developments, such as regulatory actions affecting environmental activities; the imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls; adverse weather conditions or natural disasters, such as hurricanes and earthquakes; and labor disputes, which may lead to increased costs or disruption of operations.

 

25

 

 

This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative, but by no means exhaustive.

 

Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for the Company.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Our management evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our President and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected but we believe the controls and procedures do provide a reasonable assurance.

 

(b) Changes in the Company’s Internal Controls Over Financial Reporting

 

There have been no changes in internal control over financial reporting that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the internal control over financial reporting.

 

26

 

 

Part II - Other Information

 

Item 1. Legal Proceedings

 

There are no legal proceedings which are pending or have been threatened against us or any of our officers, directors or control persons of which management is aware.

 

Item 1A. Risk Factors

 

Not applicable to smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Proceeds

 

Recent Sales of Unregistered Securities

 

We have not sold any restricted securities during the three and six months ended June 30, 2026.

 

Use of Proceeds of Registered Securities

 

None; not applicable.

 

Purchases of Equity Securities by Us and Affiliated Purchasers

 

During the six months ended June 30, 2026, we have not purchased any equity securities nor have any officers or directors of the Company.

 

Item 3. Defaults Upon Senior Securities

 

We are not aware of any defaults upon senior securities. Management has indicated they do not, at this time, intend to pursue the defaults.

 

Item 4. Mine Safety Disclosure

 

None; not applicable.

 

Item 5. Other Information

 

None; not applicable.

 

Item 6. Exhibits

 

  Exhibits No.    
  31.1   Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  32.1   Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  101.INS*   Inline XBRL Instance Document
  101.SCH*   Inline XBRL Taxonomy Extension Schema Document
  101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
  101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
  101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
  101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

  * These interactive data files are deemed “furnished” and not “filed” or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, or deemed “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise is not subject to liability under these sections.

 

27

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

China Foods Holdings Ltd.

 

Dated: August 14, 2026 By: /s/ Kong Xiao Jun
    Kong Xiao Jun
    Chief Executive Officer & Chief Financial Officer

 

28

 

 

ATTACHMENTS / EXHIBITS

EX-31.1

EX-32.1

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: form10-q_htm.xml



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings